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Abstract Clinical digestive disorders depend on the non-
adequate coupling of functioning of the gastrointestinal
tract with that of its affluent systems, namely, the pancre-
atic exocrine and the hepato-biliary secretions. The
secretion of gastrointestinal hormones is monitored by the
peripheral autonomic nervous system. However, the latter
is regulated by the central nervous system (CNS) circuitry
localized at the medullary pontine segment of the CNS. In
turn, both parasympathetic and adrenergic medullary cir-
cuitries are regulated by the pontine A5 noradrenergic
(NA) and the dorsal raphe serotonergic nuclei, respec-
tively. DR-5HT is positively correlated with the C1-Ad
medullary nuclei (responsible for adrenal gland secretion),
whereas the MR-5HT nucleus is positively correlated with
the A5-NA pontomedullary nucleus. The latter is respon-
sible for neural sympathetic activity (sympathetic nerves).
Both types of sympathetic activities maintain an alternation
with the peripheral parasympathetic branch, which is pos-
itively correlated with the enterochromaffin cells that
secrete serotonin. Serotonin displays hormonal antagonism
to the circulating catecholamines.
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Introduction
The coupling of both secretory and motility activities of the
different sections of the gastrointestinal and the biliary and
pancreatic segments of the digestive tract favors the par-
allelism of the digestive, absorptive, and motility activities
that guarantee the maximal utilization of the ingested
nutrients. However, it should also guarantee the descending
gradient of pressure, which allows the normal progression
of the nutrients with a minimum of waste. This physio-
logical target is accomplished because the different
segments of the digestive tract (esophagus, stomach, duo-
denum, small bowel, colon, and rectum) are separated by
adequate sphynctereal rings that should be chronologically
opened and closed in order to allow the progression and
impede refluxes of the ingested food. In addition to the
above, the hepato-biliary and pancreatic flowings should
pass over the biliary and pancreatic ductular channels
before reaching the choleducus, at which end the sphincter
of Oddi acts as a semaphore that requires several neuro-
autonomic and hormonal requirements before giving the
green light to allow the flow of the biliary and pancreatic
juice to the duodenum. Accordingly, these complex
motility and secretory mechanisms guarantee the sequen-
tial functioning of the different branches of the digestive
tract addressed to allow an adequate performance of the
digestive and absorptive processes; however, taking into
account the many physiological factors (hormonal as well
as ANS) that interact at these levels, it would be easy to
understand the lability of the above functioning, which is
submitted to many types of stressor agents able to interfere
with the physiology of the ANS, which is responsible for it.
Special mention should be made of the iatrogenic phar-
macological manipulations that should be included among
the most frequent causes of gastrointestinal diseases [1–3].
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Neuroautonomic and Hormonal Factors Involved
in the Gastrointestinal and Pancreato-Biliary
Physiology
Esophageal motility and emptying depends on the esoph-
ageal-gastric sphincter, which contracts and relaxes
according to the intra-gastric pH. Contractile response is
registered when the pH is low and tends to relax when it
rises. It is maximally open when gastric acid disappears.
The fact that the enhancement of gastric acidity tends to
close the pyloric sphincter also indicates that both the
esophageal and the duodenal mucosa should be protected
from the gastric acid secretion. Conversely, the duodenal
mucosa is physiologically adapted to the alkalinity of the
pancreato-biliary secretion, which is able to neutralize the
acidity of the gastric shove in such a way that an adequate
intermission of the pyloric sphincter aperture grants the
necessary accomplishment of the neutralization of the
gastric acid flow. Impairment of this physiological mech-
anism favors the ulceration of the duodenal mucosa.
Conversely, the disappearance of the gastric acid content
facilitates the duodenal-gastric reflux of bilis, bicarbonate,
and pancreatic enzymes, which are able to damage both
gastric and esophageal mucosa. This phenomenon is fre-
quently registered in patients taking omeprazole and any
other similar drugs [4].
Hormonal factors also play both physiological and
pathophysiological roles. Gastrin enhances both gastric
acid and pancreato-biliary flowing. Conversely, duodenal
hormones such as secretin, pancreozymin, and cholecys-
tokinin (CCK) enhance pancreato-biliary secretions as well
as gallbladder and biliary motility. However, these hor-
mones are coupled with the ANS mechanisms into a
complex physiological interaction in such a way that any
ANS disorder triggers the physiological unbalance
responsible for different gastrointestinal and pancreato-
biliary dysfunctions [5, 6]. In addition, it has been dem-
onstrated that CCK plays primordial physiological and
pathophysiological roles in the motility of the colon [7, 8];
in addition, this gastrointestinal hormone crosses the blood
brain barrier, at which level it interacts with CCK receptors
located at the dorsal raphe serotonergic nucleus DR-5HT
and provokes satiety [9, 10]. Underlying this physiological
phenomenon is the reduction of both gastrointestinal
motility and secretions and the inhibition of the distal colon
motility. Thus, physicians should be aware that the phar-
macological manipulation of drugs addressed to treat
gastrointestinal diseases provokes both peripheral and CNS
effects.
According to the above, we will try to summarize the
most relevant pathophysiological and neuropharmacologi-
cal mechanisms underlying gastrointestinal and pancreato-
biliary disorders as well as the hormonal plus the ANS and
CNS mechanisms associated with them. In addition, we
will try to introduce readers into the most relevant factors
that interact with both the CNS and the ANS areas.
The Peripheral Autonomic Nervous System (ANS)
Whereas the sympathetic activity depends on two periph-
eral branches, neural and adrenal [11], parasympathetic
activity is displayed by nerves that release acetylcholine
(ACh) [3]. However, serotonin (5HT) released from the
enterochromaffin cells during parasympathetic excitation is
able to antagonize peripheral sympathetic activity [12]. In
addition, 5HT-neurons located at the myenteric plexa send
excitatory axons to the muscular longitudinal external
intestinal layer [13, 14]. Furthermore, 5HT released from
the enterochromaffin cells excites pancreatic exocrine [15–
19] and inhibits pancreatic endocrine secretion [20–22],
respectively.
Sympathetic nerves arise from the lumbar sympathetic
acetylcholinergic (ACh) neurons, whereas adrenal glands
receive excitatory axons from the thoracic sympathetic
ACh-neurons [23]. The former sympathetic branch
receives excitatory axons from the A5-NA nucleus (located
at the pontomedullary area), whereas the adrenal sympa-
thetic branch receives excitatory axons from the C1-Ad
medullary nuclei [24, 25]. Thus, taking into account that
sympathetic nerves release 80% of noradrenaline (NA),
whereas adrenal glands secrete 80% of Ad, the NA/Ad
plasma ratio reflects the proportional participation of both
sympathetic branches [26]. In addition, considering that the
A5-NA and the C1-Ad nuclei interchange inhibitory axons
[27], it should be easy to understand that the assessment of
the circulating catecholamines should afford adequate
information about the proportional participation of these
two sympathetic branches [28, 29]. Finally, it should be
known that, whereas the A5-NA neurons send inhibitory
axons to the medullary vagal (ACh) nuclei [30, 31], the
C1-Ad nuclei send and also receive axons from the med-
ullary vagal complex [27, 32].
The above-summarized crosstalk explains the fast alt-
ernancy frequently registered between the adrenal
sympathetic versus parasympathetic activity as well as the
slow alternation that might occur between the other bino-
mial (neural sympathetic vs. parasympathetic) [29]. In
addition, it should be remembered that both NA and Ad
axons inhibit Ad and NA postsynaptic neurons, respec-
tively, which are crowded with alpha-2 inhibitory receptors
[33]. This pharmacological data explains why alpha-2
agonists and/or antagonists are able to interfere with both
types of sympathetic predominance.
According to the above-summarized information, it is
understandable that an adequate assessment of the ANS
Dig Dis Sci (2009) 54:458–470 459
123
disorders should include the determination of all circulat-
ing neurotransmitters. With respect to this, we report that
our institute has assessed those parameters in some 30,000
normal and diseased subjects, not only during supine-
resting (fasting) conditions, but also after many types of
challenges (orthostasis, exercise, oral glucose, and many
CNS-acting drugs) [34–47].
Although acetylcholine is not detectable in the periph-
eral blood, the assessment of both plasma and platelet
serotonin (f-5HT and p-5HT) affords adequate information
about this parasympathetic parameter. However, consider-
ing that increased platelet aggregation triggers the
enhancement of f-5HT registered during stress periods,
which depends on the raised levels of plasma Ad [42, 44,
48], the assessment of f-5HT carried out during non-stress
periods reflects parasympathetic activity, because plasma
ACh competes with serotonin for platelet uptake. In other
words, f-5HT is positively correlated with plasma ACh
levels [49–53]. Cardiovascular parameters parallel ANS
disorders. For instance, heart rate is positively correlated
with adrenal sympathetic activity, whereas diastolic blood
pressure depends on neural sympathetic activity. With
respect to this, we have demonstrated that an accurate
assessment of these cardiovascular parameters at the 1-min
orthostasis challenge affords information that allows
knowing which of the two peripheral sympathetic branches
is predominant [28, 36–38].
Pathophysiological Data Related to Some
Gastrointestinal Diseases
Gastritis
Type A (antral) gastritis is frequently underlain by a TH-2
immunological profile (adrenal sympathetic overactivity)
and is frequently associated with duodenal ulceration [54,
55]. Parasympathetic rebounds, always registered during
nocturnal (sleep) periods, are responsible for the appear-
ance of duodenal ulcers [1, 2, 56–59]. In our long
experience with this issue, the attenuation of both the
diurnal adrenal sympathetic and the nocturnal parasympa-
thetic rebounds is enough to revert both the uncoping stress
situation and the gastroduodenal damage. This target is
reached through neuropharmacological therapy, which
includes small doses of NA uptake inhibitors (at diurnal
period) plus small doses of NA and 5HT uptake inhibitors
before bed. With respect to the above, it should be
remembered that the iatrogenic effect triggered by drugs
that interfere with the K+ and NA+ versus H+ pumps
interchange destroys the mucosal barrier, provokes the
disappearance of antral acidity, and facilitates duodeno-
gastric reflux because of the permanent antral alkalinity
[59–61]. In addition, evidence has demonstrated that heli-
cobacter pylori favors the TH-1 immunity profile, which
protects against malignancy [62]. Furthermore, the gastric
to esophageal reflux of bilis is responsible for esophagitis,
which is also provoked by this iatrogenic factor. The
esophagic sphincter remains open because of the alkalin-
ization of the gastric content. This phenomenon is
enhanced during the recumbent nocturnal periods when
parasympathetic predominance increases alkaline-pancre-
ato-biliary secretions. This iatrogenic phenomenon is more
evident in cholecystectomized patients, because bilis is not
stored in the gallbladder. Accordingly, we believe that an
adequate neuropharmacological therapy is the only thera-
peutical strategy able to revert the above-mentioned
iatrogenic deleterious pathophysiologic disorders [4, 33,
63–70].
Additional information has demonstrated that type B
gastritis is present in subjects affected by neural sympa-
thetic predominance. These subjects present with a TH-1
immunological profile because they have low levels of
circulating Ad. This catecholamine favors the appearance
of malignant diseases because it interferes with the
destruction of malignant cells by the natural killer (NK)
cells. This issue was demonstrated and published by our
research group in 1987 [24, 42, 71–79] and has been
confirmed by other researchers [80]. Thus, any neuro-
pharmacological therapy of patients affected by malignant
diseases should include the reversion of the adrenal over
the neural sympathetic predominance.
Reflux Esophagitis
This disorder is also underlain by diurnal adrenal sympa-
thetic overactivity that is reversed by parasympathetic
overactivity in the nocturnal periods. Hence, these patients
should also be treated with neuropharmacological manip-
ulation addressed to enhance diurnal neural sympathetic
activity. With respect to the above, we should emphasize
that the nocturnal parasympathetic rebound, always regis-
tered in these patients, allows the duodenal and gastric
reflux to the esophagus because the neural sympathetic
hypoactivity allows the permanent aperture of both the
pyloric and cardial sphincters [81, 82]. This phenomenon
obliges attempting the normalization of the sleep disorder
that is always present in these patients. With respect to this,
it has been exhaustively demonstrated that in normal sub-
jects, adrenal sympathetic activity reaches near zero values
10–15 min after the supine-resting state [34, 64, 69, 70].
On the contrary, neural sympathetic activity (which closes
the sphincter) fades gradually and reaches minimal values
(never zero values) at the REM sleep periods (90 min after
the sleep initiation) [34, 83]. Thus, the absence of the slow
wave sleep (SWS) period always registered in stressed
460 Dig Dis Sci (2009) 54:458–470
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mammals [84] interferes with the sphincter closure and
favors biliary-gastro-esophageal reflux. Accordingly, nor-
malization of the sleep disorder should constitute an
imperative therapeutic step, addressed to reach the above
target. However, a scientific neuropharmacological
manipulation, but not the administration of benzodiaze-
pines, should be prescribed. With respect to this, we would
refer readers to our last books [24, 25].
With respect to the above, we will summarize the CNS
disorders responsible for the raised levels of adrenaline and
cortisol registered in stressed patients. The raised cortisol
plasma levels depend on the hypersecretion of corticotro-
pin-releasing hormone (CRH) by the hypothalamus. Dorsal
raphe axons release serotonin at this level, which excites
CRH neurons. In addition, DR-5HT axons excite also the
C1-Ad nuclei, which enhance adrenal sympathetic activity
[85]. Over-excitation of the C1-Ad nuclei (adrenal sym-
pathetic activity) inhibits the A5-NA nucleus, which is
responsible for the peripheral neural sympathetic activity.
Thus, any neuropharmacological treatment of the stress
situation should include the reversion of the C1-Ad over
A5-NA predominance. This target is reached with the
administration of a small dose of drugs that inhibits the
uptake of NA at diurnal periods and a small dose of drugs
that inhibits both the NA and the 5HT uptake at nocturnal
periods. This manipulation also improves the sleep cycle.
The above neuropharmacological strategy fits well with the
successful neuropharmacological treatment of duodenal
ulcer with doxepin (inhibits both NA and 5HT uptake)
reported many years ago [61] and since then further
confirmed.
Irritable Bowel Syndrome and Biliary Dyskinesia
Neural sympathetic activity contracts pyloric, ileocecal,
and Oddi sphincters and, in addition, contracts the sig-
moidal rectal junction. At the same time, this branch of the
peripheral autonomic nervous system (ANS) antagonizes
the dilator effect triggered by CCK at these levels; hence,
overactivity of this ANS branch interferes with the CCK
released during the postprandial periods and interrupts the
biliary, ileal, and sigmoidal flow to the post-junctional
Table 1 Neuroautonomic plus immunological profiles underlying gastrointestinal and pancreato-biliary diseases
Adrenal [ neural Neural [ adrenal
Sympathetic predominance Sympathetic predominance
Central pathways activated C1(Ad) A5(NA)
Neurochemical profile Uncoping stress Endogenous depression
Immunological profile TH-2 TH-1
ANS profile Ad. S. P. S. N. S. P. S.
Gastrointestinal diseases
Reflux esophagitis x x
Type A gastritis x x
Type B gastritis x
Gastric ulcer x x
Duodenal ulcer x x
Acute pancreatitis x x
Biliary dyskinesia x x
Spastic colon x
Nervous diarrhea x x
Ulcerative colitis x x
Granulomatous colitis (Crohn’s) x
Carcinoid syndrome x x
Pancreatic cyst fibrosis x x
Malignant diseases x
Uncoping stress: Adrenal gland secretion of catecholamines (Ad 80%, NA 10%, and DA 10%) predominates over sympathetic nerve release of
catecholamines (NA 80–90% and DA 10–20%). Overactivity of the CNS C1(Ad) nuclei triggers excitation of the vagal (medullary) nuclei, which
is responsible for the peripheral parasympathetic nerve activity. Thus, alternance of these two ANS peripheral branches is frequently registered in
patients affected by uncoping stress syndrome (adrenal stage = Ad. S.; parasympathetic stage = P. S.). Predominance of both Ad and cortisol are
responsible for the TH-2 immunological predominance
Endogenous depression: Absolute predominance of neural over adrenal sympathetic activity underlies this CNS and ANS profile (neural
sympathetic stage = N. S.). At the CNS level, the A5(NA) nucleus exerts maximal inhibition of both the C1(Ad) and vagal (medullary) nuclei.
This CNS disorder is responsible for the disappearance of both adrenal and parasympathetic peripheral activities. In addition, the inhibition of the
adrenocortical glands is responsible for the disinhibition of the thymus, which redounds in the TH-1 immunological profile
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segments [5, 7, 8, 86–90]. The above phenomena are reg-
istered during the spastic colon period of the IBS. The fact
that clonidine, a CNS-acting alpha-2 agonist that sup-
presses both neural and adrenal sympathetic overactivities
by acting at the A5-NA and/or C1-Ad CNS nuclei, supports
our postulation [87–102]. Both CNS nuclei are crowded by
alpha-2 inhibitory receptors; hence, the drug would act at
the hyperactive, but not at the hypoactive nucleus. Fur-
thermore, considering that both CNS nuclei interchange
inhibitory axons, alpha-2 agonists and/or antagonists are
able to revert the physiological predominance of any of
both systems. In addition, it is important to know that
whereas the C1-Ad nuclei are positively correlated with the
dorsal raphe (DR) serotonergic nucleus, the A5-NA
nucleus parallels the activity of the median raphe (MR)
serotonergic nucleus (MR-5HT) [103, 104]. Finally, it
should be known that both serotonergic nuclei interchange
inhibitory axons. Summarizing the above, it has been
established that whereas the DR-5HT + C1-Ad hyperac-
tivity is responsible for the uncoping stress syndrome, the
MR-5HT + A5-NA binomial predominates in patients
affected by endogenous depression as well as in patients
affected by neural sympathetic overactivity (essential
hypertension, hyperinsulinism, rheumatoid arthritis, and all
TH-1 autoimmune diseases) [3, 24, 101–105]. At the
gastrointestinal level, patients with reflux esophagitis [81,
82], duodenal ulcer [59, 60], ulcerative colitis [100, 106],
and diarrheic periods (IBS) [88, 107, 108], as well as
showing mucosal eosinophilia, always present adrenal
sympathetic predominance and a TH-2 immunological
profile, whereas patients affected by the spastic colon,
biliary hypokinesia (no gallbladder emptying), Crohn’s
disease, etc., always have both underlying neural sympa-
thetic predominance and TH-1 immunological profile [24,
25, 72, 94, 105, 109]. The above neuroautonomic and
immunological information has allowed us to successfully
treat hundreds of patients affected by such gastrointestinal
disorders [108–115] (Table 1, Figs. 1, 2).
Hyperactivity of the adrenal sympathetic system
underlies the diarrheic period of the IBS. At this stage,
gastrointestinal and pancreatic sphincters remain open. The
continued overflow of bilis is diverted to the duodenum;
however, some fraction may reflux to the stomach and
esophagus, whereas some other fraction of the biliary flow
is discharged into the small bowel, at which level it
enhances motility. The resultant hyper-peristalsis is
enhanced by the inhibition of the release of serotonin from
the myenteric plexa level [14]. These neurons send excit-
atory axons to the longitudinal muscular intestinal
layer (which increases intestinal tone and interferes
Fig. 1 Experimental evidence: physiological, pathophysiological,
neuropharmacological, clinical, and therapeutic evidence dealing
with the irritable bowel syndrome and biliary dyskinesia. Effects of
the intramuscularly injected CCK (0.5 U/kg). CCK triggered the
gallbladder to empty in a normal subject (upper). One week later,
dihydroergotamine (DHE 1 mg) intramuscularly injected 45 min
before CCK interfered with the gallbladder emptying (lower) and in
addition provoked abdominal pain at the right-upper abdominal side.
At the plasma level, DHE provoked a significant rise of the plasma
noradrenaline (NA) and an increase of the NA/Ad plasma ratio
(neural sympathetic overactivity). Furthermore, significant reduction
of the f5HT/p5HT ratio (hypo-parasympathetic activity) was regis-
tered after DHE administration. Finally, the above circulating
neurotransmitters profile triggered by DHE administration was further
reverted after clonidine administration
462 Dig Dis Sci (2009) 54:458–470
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with peristalsis); thus, depletion of this serotonergic plexus
reduces intestinal tone and facilitates peristalsis, which
depends on the circular muscular layer. Considering that
neural sympathetic and adrenal sympathetic activities are
positively correlated with the above muscular layers,
respectively, the disappearance of the spasticity (which
depends on the external muscular layer) favors the activity
of the circular (internal) muscular layer that enhances
peristalsis. Summarizing the above, neural sympa-
thetic activity is positively correlated with the myenteric
(5HT) and longitudinal muscular layer responsible for
the intestinal tone, whereas adrenal sympathetic activity
favors intestinal hypotony and peristalsis [18, 116–120]
(Figs. 3, 4).
At the CNS level, a great bulk of data allows associating
neural sympathetic activity with the MR-5HT nucleus,
whereas the adrenal sympathetic activity parallels the
DR-5HT nucleus activity. Predominance of the former is
associated with depression, whereas the latter CNS cir-
cuitry predominates during the uncoping stress syndrome
[25, 39–41, 43, 44, 88, 103, 104, 121–124]. These findings
fit well with the psychiatric profiles registered during both
types of IBS clinical periods. The above comments are
supported by the routine assessment of circulating neuro-
transmitters in some 30,000 normal and diseased subjects,
not only during supine-resting condition but also after
many types of stressor agents and CNS-acting drugs [35,
37, 44, 46, 123, 125–127].
In summary, the assessment of circulating neurotrans-
mitters carried out in our institute throughout the last 30
years showed that a lowered NA/Ad ratio (\3) is registered
during the diarrheic period, whereas the high NA/Ad ratio
([7) is found during the spastic colon period [39–41, 43,
88, 120, 122, 128, 129].
Both the raised plasma serotonin (f5HT) and the reduced
platelet serotonin (p5HT) levels registered during the
diarrheic periods were reverted at the spastic colon period.
The reversion of the above serotonin parameters should be
associated with the reduction of platelet aggregation, which
also paralleled the raised levels of circulating adrenaline,
and in addition, to the fading of the adrenal sympathetic
activity, which triggers platelet aggregation; thus, serotonin
stored in the platelets is released to the plasma and further
metabolized.
Commentary Dealing with the Pathophysiology
and Therapeutical Approaches of Pancreatic
Inflammatory Diseases as Well as the Carcinoid
Syndrome
Pancreatitis
We have successfully treated 41 patients affected by acute
pancreatitis; all patients have done well throughout the last
4 decades. All symptoms disappeared abruptly after the
first intramuscular injection of clonidine (0.15 mg); plasma
amylase levels were normalized within the first 6 h. Clo-
nidine was administered every 6 h throughout the first 48 h,
and then it was progressively spaced. The dramatic
improvement triggered by this alpha-2 (CNS-acting) ago-
nist should be attributed to facts showing that the
pancreatic innervation depends on the C1-Ad medullary
nuclei, which also innervates salivary glands. The latter is
consistent with findings showing that clonidine triggered
Fig. 2 Effects of clonidine on the distal colon and biliary motility of
a patient affected by spastic colon syndrome plus biliary dyskinesia.
Clonidine (0.15 mg intramuscularly injected) suppresses the diarrheic
syndrome in a patient affected by irritable bowel syndrome (diarrheic
period). Clonidine suppressed also the rectal hyperactivity and
enhanced the sigmoidal tone (sigmoidal rectal junction). The X-ray
study, carried out 3 days before this test, showed a normal gallbladder
emptying after the Boyden (test) meal. However, the administration
of oral clonidine (0.15 mg three times daily) reverted not only the
distal colon motility profile, but also the diarrheic syndrome, and, in
addition, triggered an increase of the sigmoidal tone plus the rectal
hypomotility. No gallbladder emptying was registered during a
second radiological study performed 8 days later during the clonidine
trial (at which period the patient presented constipation and abdom-
inal pain at both the right-upper hypochondrium and the left-lower
abdominal zone). Further, a small dose of mianserine (an alpha-2
central-acting antagonist) intramuscularly injected reverted both the
gallbladder and the colonic spasticity and in addition suppressed
abdominal pains [12, 96]
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dry mouth [130, 131]. In addition, we demonstrated that
clonidine relieves all types of pancreatic pain, which
should be attributed to the reduction of the flow of pan-
creatic juice [6–8, 15–17, 20–22, 45, 51, 87, 89, 90, 95–97,
107, 109, 121, 131–147].
Carcinoid Syndrome
We have successfully treated nine patients affected by this
disease (no failures). Our neuropharmacological therapeu-
tic strategy is addressed to reduce the overwhelming
Fig. 3 Adrenal sympathetic activity. This peripheral branch of the
autonomic nervous system (ANS) depends on the secretion of
catecholamines by the adrenal gland (80% of Ad + 20% of NA +
10% DA). These glands receive excitatory axons from the thoracic
presynaptic (ACh) neurons. These ACh neurons depend on the
excitatory drives arising from the C1-Ad medullary nuclei, which in
addition send inhibitory axons to both the A5(NA) and the A6(NA)
nuclei. Furthermore, these subjects also present raised levels of
plasma cortisol (CRT), which depends on the DR-5HT axons. This
serotonergic nucleus interchanges excitatory drives with the C1(Ad)
nuclei. Finally, both DR(5HT) and C1(Ad) axons excite the
hypothalamic paraventricular nucleus. Furthermore, cortisol crosses
the blood brain barrier and excites the DR-5HT. This positive
feedback explains the raised levels of circulating Ad and CRT always
registered in these patients. The above anatomical and physiological
and pathophysiological mechanisms are reverted by administration of
NA uptake inhibitors such as desipramine. Finally, the raised levels of
Ad and CRT in the plasma are consistent with the bulk of clinical
syndromes underlain by the uncoping stress syndrome
464 Dig Dis Sci (2009) 54:458–470
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parasympathetic activity that underlies this syndrome. This
target was reached through the enhancement of the neural
sympathetic activity that annuls both the adrenal and
parasympathetic oscillations always registered in these
patients [18, 19, 148]. With respect to the above, it is well
established that parasympathetic nerves excite entero-
chromaffin cells. Serotonin released by these cells to the
portal vein is partially uptaked by the liver; however, some
Fig. 4 Neural sympathetic activity. Neural sympathetic activity
depends on the sympathetic nerves’ release of NA (90%) + DA
(10%). This branch of the peripheral autonomic nervous system
(ANS) is positively correlated with activity of the ponto-medullary
A5(NA) neurons, which excite the spinal sympathetic neurons and
inhibit the C1(Ad) medullary nuclei (responsible for the adrenal
glands secretion). In addition, A5(NA) axons inhibit the medullary
vagal complex. The absence of C1(Ad) activity redounds in the
hypoactivity of the DR(5HT) neurons. Serotonin released from these
axons is the most important factor that initiates and prolongs the CRH
secretion by the PVN hypothalamic nucleus. The minimization of this
factor is consistent with the moderated rise of plasma CRT always
registered during neural sympathetic overactivity. In addition, it has
been demonstrated that sympathetic nerves inhibit adrenal gland
secretion, directly by acting at alpha-2 receptors located at these
glands. This is consistent with the raised NA/Ad plasma ratio
registered in these patients. Furthermore, overactivity of the sympa-
thetic nerves provokes the vascular, bronchial, sphincteral
(gastrointestinal, urinary) contraction always present at this
circumstance
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fraction escapes to this obstacle and reaches the lung at
which level some other fraction of 5-HT is taken up by the
pulmonary neuroendocrine cell (PNEC). The serotonin that
escapes from lung and platelet uptake remains free in the
plasma (f-5HT) and excites medullary area postrema (AP),
which is located outside the blood brain barrier [116, 119].
The excitation of this nucleus, which is crowded by 5HT3
receptors [149], triggers the activation of the medullary
vagal complex (nucleus tractus solitarii = NTS), which is
responsible for the hyper-secretion of serotonin by the
enterochromaffin cells (Bezold-Jarisch reflex). The neuro-
pharmacological manipulation addressed to enhance neural
sympathetic activity (NA plasma level) provokes sustained
clinical improvement plus the significant reduction of cir-
culating serotonin [15, 17–19, 141, 150, 151].
Not only the carcinoid syndrome, but also cystic fibro-
sis, pancreatic and hepatic cysts have been successfully
treated with the same neuropharmacological manipulation.
These findings are consistent with the demonstration that
the two latter diseases are underlain by raised levels of
circulating serotonin as well as by lower NA plasma val-
ues. The above results indicate that adrenal sympathetic
and parasympathetic over neural sympathetic predomi-
nance is responsible for the hyperactivity of the
enterochromaffin cells that provokes the physiological
disorders underlying carcinoid syndrome and cystic fibrosis
of the pancreas [15–17, 131–133]. The above phenomena
depend on the excitation of the C1-Ad nuclei by ACh-NTS
axons [152, 153].
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